Ann F Chambers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6945613/publications.pdf

Version: 2024-02-01

		7551	9311
247	22,509	77	143
papers	citations	h-index	g-index

262	262	262	20955
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2002, 2, 563-572.	12.8	3,414
2	Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute, 1997, 89, 1260-1270.	3.0	1,438
3	Multistep Nature of Metastatic Inefficiency. American Journal of Pathology, 1998, 153, 865-873.	1.9	1,085
4	Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutrition and Cancer, 1996, 26, 167-181.	0.9	440
5	Role of osteopontin in tumour progression. British Journal of Cancer, 2004, 90, 1877-1881.	2.9	385
6	Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton. Cancer Research, 2008, 68, 6241-6250.	0.4	377
7	Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling. Journal of the National Cancer Institute, 2002, 94, 513-521.	3.0	358
8	Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth. European Journal of Cancer, 2010, 46, 1181-1188.	1.3	326
9	Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies. Clinical Cancer Research, 2004, 10, 184-190.	3.2	323
10	Invadopodia Are Required for Cancer Cell Extravasation and Are a Therapeutic Target for Metastasis. Cell Reports, 2014, 8, 1558-1570.	2.9	310
11	In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magnetic Resonance in Medicine, 2006, 56, 1001-1010.	1.9	286
12	Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases. Breast Cancer Research and Treatment, 2003, 82, 199-206.	1.1	281
13	In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magnetic Resonance in Medicine, 2006, 55, 23-29.	1.9	280
14	Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Research, 2002, 62, 2162-8.	0.4	272
15	Does tumour dormancy offer a therapeutic target?. Nature Reviews Cancer, 2010, 10, 871-877.	12.8	270
16	Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer and Metastasis Reviews, 1995, 14, 279-301.	2.7	251
17	Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Letters, 1997, 112, 127-133.	3.2	231
18	The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis. Current Molecular Medicine, 2001, 1, 621-632.	0.6	205

#	Article	IF	Citations
19	MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?. Cancer Research, 2009, 69, 5292-5293.	0.4	202
20	Osteopontin expression in a group of lymph node negative breast cancer patients. , 1998, 79, 502-508.		197
21	Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 1999, 18, 4237-4246.	2.6	186
22	Osteopontin expression in lung cancer. Lung Cancer, 1996, 15, 311-323.	0.9	178
23	Osteopontin and Its Receptor Î±vÎ²₃Integrin Are Coexpressed in the Human Endometrium during the Menstrual Cycle But Regulated Differentially. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4991-5000.	1.8	177
24	Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids, 1995, 30, 1139-1143.	0.7	176
25	Inhibition of Proliferation of Estrogen Receptorâ€“Negative MDA-MB-435 and â€“Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination. Journal of Nutrition, 1997, 127, 544S-548S.	1.3	176
26	A Flavonoid Fraction from Cranberry Extract Inhibits Proliferation of Human Tumor Cell Lines. Journal of Nutrition, 2004, 134, 1529-1535.	1.3	173
27	Dormancy of Solitary Metastatic Cells. Cell Cycle, 2006, 5, 1744-1750.	1.3	168
28	Cancer spread and micrometastasis development: Quantitative approaches for in vivo models. BioEssays, 2002, 24, 885-893.	1.2	167
29	Critical Steps in Hematogenous Metastasis. Surgical Oncology Clinics of North America, 2001, 10, 243-255.	0.6	162
30	Role of the metastasisâ€promoting protein osteopontin in the tumour microenvironment. Journal of Cellular and Molecular Medicine, 2010, 14, 2037-2044.	1.6	162
31	Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene, 2006, 25, 409-418.	2.6	157
32	Plasma osteopontin. Cancer, 2002, 95, 506-512.	2.0	152
33	Î²1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence. Clinical Cancer Research, 2011, 17, 7219-7223.	3.2	151
34	Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer. Clinical Cancer Research, 2006, 12, 3337-3343.	3.2	147
35	Osteopontin and Its Receptor ÂvÂ3 Integrin Are Coexpressed in the Human Endometrium during the Menstrual Cycle But Regulated Differentially. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4991-5000.	1.8	146
36	Tumor Dormancy and Cancer Stem Cells: Implications for the Biology and Treatment of Breast Cancer Metastasis. Breast Disease, 2007, 26, 87-98.	0.4	139

#	Article	IF	Citations
37	The Biology of Metastasis to a Sanctuary Site. Clinical Cancer Research, 2007, 13, 1656-1662.	3.2	138
38	Osteopontin and Î² ₃ Integrin Are Coordinately Expressed in Regenerating Endothelium In Vivo and Stimulate Arg-Gly-Aspâ€"Dependent Endothelial Migration In Vitro. Circulation Research, 1995, 77, 665-672.	2.0	136
39	Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science, 1984, 224, 998-1001.	6.0	134
40	Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 2000, 78, 465-475.	1.2	132
41	Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer. Molecular Cancer Research, 2011, 9, 834-844.	1.5	131
42	Molecular biology of breast cancer metastasis Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Research, 2000, 2, 400-7.	2.2	124
43	The role of osteopontin in breast cancer: clinical and experimental studies. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 419-429.	1.0	123
44	Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 2003, 22, 1198-1205.	2.6	123
45	Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis. Journal of Immunology, 2003, 171, 1085-1093.	0.4	123
46	Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clinical and Experimental Metastasis, 1994, 12, 357-367.	1.7	120
47	Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. Journal of Cellular Biochemistry, 2007, 102, 859-868.	1.2	120
48	Three-dimensional High-Frequency Ultrasound Imaging for Longitudinal Evaluation of Liver Metastases in Preclinical Models. Cancer Research, 2005, 65, 5231-5237.	0.4	115
49	Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 5547-5551.	3.3	114
50	Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clinical and Experimental Metastasis, 1993, 11, 377-390.	1.7	113
51	Secreted phosphoprotein mrna is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. International Journal of Cancer, 1990, 46, 133-137.	2.3	112
52	Solitary cancer cells as a possible source of tumour dormancy?. Seminars in Cancer Biology, 2001, 11, 271-276.	4.3	111
53	Identification of the major phosphoprotein secreted by many rodent cell lines as 2AR/osteopontin: Enhanced expression in H-RAS-transformed 3T3 cells. Biochemical and Biophysical Research Communications, 1988, 157, 166-173.	1.0	108
54	Clinical targets for anti-metastasis therapy. Advances in Cancer Research, 2000, 79, 91-121.	1.9	107

#	Article	IF	Citations
55	Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Molecular Cancer, 2007, 6, 6.	7.9	107
56	Pre- and post-translational regulation of osteopontin in cancer. Journal of Cell Communication and Signaling, 2011, 5, 111-122.	1.8	100
57	Functional analysis of bone sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by recombinant peptide expression and site-directed mutagenesis. Bone, 2000, 27, 795-802.	1.4	99
58	Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. Journal of Cellular Biochemistry, 1995, 57, 680-690.	1.2	96
59	p53 Mutation, Expression, and DNA Ploidy in Evolving Gliomas: Evidence for Two Pathways of Progression. Journal of the National Cancer Institute, 1994, 86, 1011-1017.	3.0	95
60	Overcoming obstacles to metastasis - defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. Journal of Cellular Biochemistry, 1994, 56, 48-51.	1.2	94
61	Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11080-11084.	3.3	94
62	Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer. American Journal of Pathology, 2006, 169, 233-246.	1.9	94
63	Tumour dormancy in breast cancer: an update. Breast Cancer Research, 2007, 9, 208.	2.2	93
64	Molecular mechanisms of metastasis. Cancer and Metastasis Reviews, 2006, 25, 203-220.	2.7	92
65	Osteopontin induces multiple changes in gene expression that reflect the six â€œhallmarks of cancerâ€•in a model of breast cancer progression. Molecular Carcinogenesis, 2005, 43, 225-236.	1.3	91
66	Chapter 3 Tumor Dormancy and Metastasis. Advances in Cancer Research, 2009, 102, 67-101.	1.9	91
67	Early Steps in Hematogenous Metastasis of B16F1 Melanoma Cells in Chick Embryos Studied by High-Resolution Intravital Videomicroscopy. Journal of the National Cancer Institute, 1992, 84, 797-803.	3.0	90
68	The Role of Apoptosis in Tumor Progression and Metastasis. Current Molecular Medicine, 2003, 3, 631-642.	0.6	89
69	Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 65A, 4-14.	1.1	89
70	Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clinical and Experimental Metastasis, 2005, 22, 663-673.	1.7	89
71	Dietary Genistein Reduces Metastasis in a Postsurgical Orthotopic Breast Cancer Model. Cancer Research, 2005, 65, 3396-3403.	0.4	89
72	Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435. Clinical and Experimental Metastasis, 2006, 23, 123-133.	1.7	85

#	Article	IF	Citations
73	The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clinical and Experimental Metastasis, 1999, 17, 111-117.	1.7	84
74	Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clinical and Experimental Metastasis, 2003, 20, 77-84.	1.7	84
75	Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney International, 1999, 56, 74-82.	2.6	83
76	Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic,ras-transformed NIH 3T3 cells. Molecular Carcinogenesis, 1992, 5, 238-245.	1.3	82
77	Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clinical and Experimental Metastasis, 1993, 11, 103-112.	1.7	82
78	Quantitative genetic analysis of tumor progression. Cancer and Metastasis Reviews, 1985, 4, 173-192.	2.7	81
79	Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. , 2000, 77, 487-498.		81
80	Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. Oncotarget, 2016, 7, 8839-8849.	0.8	80
81	Identification of a ras-Activated Enhancer in the Mouse Osteopontin Promoter and Its Interaction with a Putative ETS-Related Transcription Factor Whose Activity Correlates with the Metastatic Potential of the Cell. Molecular and Cellular Biology, 1995, 15, 476-487.	1.1	77
82	Tumor Angiogenesis Predicts Recurrence in Invasive Colorectal Cancer When Controlled for Dukes Staging. American Journal of Surgical Pathology, 1996, 20, 1260-1265.	2.1	77
83	Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Molecular Cancer Research, 2003, 1, 810-9.	1.5	76
84	Clonal Heterogeneity, Experimental Metastatic Ability, and p21 Expression in H-ras-Transformed NIH 3T3 Cells. Journal of the National Cancer Institute, 1988, 80, 484-490.	3.0	75
85	In Vivo Inhibition of Growth of Human Tumor Lines by Flavonoid Fractions From Cranberry Extract. Nutrition and Cancer, 2006, 56, 86-94.	0.9	75
86	Brain Metastases of Breast Cancer. Breast Disease, 2007, 26, 139-147.	0.4	75
87	Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. Journal of Cellular Biochemistry, 1994, 54, 247-255.	1.2	74
88	ras mutation and expression of theras-regulated genes osteopontin and cathepsin L in human esophageal cancer. , 1997, 72, 739-745.		69
89	Osteopontin and colon cancer progression. Clinical and Experimental Metastasis, 2003, 20, 85-90.	1.7	69
90	Myxoma Virus Oncolysis of Primary and Metastatic B16F10 Mouse Tumors In Vivo. Molecular Therapy, 2008, 16, 52-59.	3.7	69

#	Article	IF	Citations
91	In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis. Investigative Radiology, 2011, 46, 718-725.	3.5	69
92	Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clinical and Experimental Metastasis, 1992, 10, 365-370.	1.7	68
93	Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Research and Treatment, 2001, 70, 197-204.	1.1	64
94	Intravital videomicroscopy of the chorioallantoic microcirculation: A model system for studying metastasis. Microvascular Research, 1992, 44, 185-199.	1.1	62
95	Time-Course Characterization of the Computed Tomography Contrast Enhancement of an Iodinated Blood-Pool Contrast Agent in Mice Using a Volumetric Flat-Panel Equipped Computed Tomography Scanner. Investigative Radiology, 2006, 41, 384-390.	3.5	62
96	Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Research, 2008, 10, R62.	2.2	62
97	Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): A new proteomic urinary test for patients with urolithiasis. Journal of Clinical Laboratory Analysis, 2004, 18, 170-175.	0.9	59
98	Effects of the Disintegrin Eristostatin on Individual Steps of Hematogenous Metastasis. Experimental Cell Research, 1995, 219, 571-578.	1.2	58
99	Quantification of cancer cell extravasation in vivo. Nature Protocols, 2016, 11, 937-948.	5.5	58
100	Specificity of cell-cell interactions in sea urchin embryos. Developmental Biology, 1977, 56, 343-355.	0.9	57
101	Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women. Clinical Biochemistry, 1996, 29, 231-239.	0.8	57
102	Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. International Journal of Cancer, 2012, 131, 276-286.	2.3	55
103	Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Laboratory Investigation, 2011, 91, 1181-1187.	1.7	53
104	Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. Journal of Cellular Biochemistry, 1996, 61, 402-409.	1.2	52
105	Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. , 1998, 77, 82-93.		52
106	Multi-Platform Whole-Genome Microarray Analyses Refine the Epigenetic Signature of Breast Cancer Metastasis with Gene Expression and Copy Number. PLoS ONE, 2010, 5, e8665.	1.1	52
107	The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Research and Treatment, 2008, 112, 243-254.	1.1	51
108	Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. British Journal of Cancer, 2012, 107, 840-846.	2.9	51

#	Article	IF	Citations
109	Invadopodia are chemosensing protrusions that guide cancer cell extravasation to promote brain tropism in metastasis. Oncogene, 2019, 38, 3598-3615.	2.6	51
110	A New Model for Lymphatic Metastasis: Development of a Variant of the MDA-MB-468 Human Breast Cancer Cell Line that Aggressively Metastasizes to Lymph Nodes. Clinical and Experimental Metastasis, 2005, 22, 351-361.	1.7	50
111	Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 769-776.	0.4	47
112	Identification of four classes of cell surface antigens appearing at gastrulation in sea urchin embryos. Developmental Biology, 1978, 63, 179-186.	0.9	46
113	Non-RGD domains of osteopontin promote cell adhesion without involving Î±v integrins. , 1996, 62, 123-131.		46
114	Human Isopentenyl Diphosphate:Dimethylallyl Diphosphate Isomerase: Overproduction, Purification, and Characterization. Archives of Biochemistry and Biophysics, 1996, 332, 30-34.	1.4	45
115	Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet, The, 1998, 351, 1170-1173.	6.3	45
116	Osteopontin Induction of Hyaluronan Synthase 2 Expression Promotes Breast Cancer Malignancy. Journal of Biological Chemistry, 2006, 281, 24381-24389.	1.6	45
117	Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 114, 503-511.	1.1	45
118	Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Research, 2002, 62, 887-91.	0.4	44
119	Osteopontin identified as colon cancer tumor progression marker. Comptes Rendus - Biologies, 2003, 326, 1041-1043.	0.1	43
120	Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncology, 2009, 5, 1083-1098.	1.1	43
121	Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy. Translational Oncology, 2015, 8, 176-184.	1.7	43
122	Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. International Journal of Cancer, 2008, 123, 526-534.	2.3	42
123	Influence of diet on metastasis and tumor dormancy. Clinical and Experimental Metastasis, 2009, 26, 61-66.	1.7	42
124	The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Human Pathology, 1996, 27, 955-963.	1.1	41
125	Three-Dimensional Imaging and Quantification of Both Solitary Cells and Metastases in Whole Mouse Liver by Magnetic Resonance Imaging. Cancer Research, 2009, 69, 8326-8331.	0.4	41
126	Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. Journal of Cellular Biochemistry, 2002, 84, 420-432.	1.2	40

#	Article	IF	Citations
127	BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clinical and Experimental Metastasis, 2008, 25, 727-740.	1.7	40
128	Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Molecular Cancer Therapeutics, 2005, 4, 1065-1075.	1.9	37
129	New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?. Apmis, 2008, 116, 552-568.	0.9	37
130	New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs. Clinical Chemistry, 2009, 55, 895-903.	1.5	37
131	Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors. Journal of Histochemistry and Cytochemistry, 2008, 56, 57-66.	1.3	35
132	Gene signatures of breast cancer progression and metastasis. Breast Cancer Research, 2011, 13, 201.	2.2	35
133	Noninvasive Quantification of Tumor Volume in Preclinical Liver Metastasis Models Using Contrast-Enhanced X-Ray Computed Tomography. Investigative Radiology, 2008, 43, 92-99.	3.5	34
134	Preclinical Drug Development Must Consider the Impact on Metastasis. Clinical Cancer Research, 2009, 15, 4529-4530.	3.2	34
135	Ovarian Cancer Biomarkers in Urine. Clinical Cancer Research, 2006, 12, 323-327.	3.2	33
136	Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H2258-H2265.	1.5	32
137	Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clinical and Experimental Metastasis, 2009, 26, 121-131.	1.7	32
138	An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis¹This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journalâ€™s usual peer review process.. Biochemistry and Cell Biology, 2012, 90, 22-38.	0.9	32
139	Stage of Breast Cancer Progression Influences Cellular Response to Activation of the WNT/Planar Cell Polarity Pathway. Scientific Reports, 2014, 4, 6315.	1.6	32
140	BRCA2 inhibition enhances cisplatinâ€•mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology, 2014, 8, 1429-1440.	2.1	32
141	A Human Promyelocyte mRNA Transiently Induced by TPA Is Homologous to Yeast IPP Isomerase. Genomics, 1994, 20, 129-131.	1.3	31
142	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Research, 2014, 16, R8.	2.2	31
143	Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1139, 77-83.	1.8	30
144	Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). Angiogenesis, 1998, 2, 373-379.	3.7	30

#	Article	IF	Citations
145	Assessing Cancer Cell Migration and Metastatic Growth In Vivo in the Chick Embryo Using Fluorescence Intravital Imaging. Methods in Molecular Biology, 2012, 872, 1-14.	0.4	30
146	Famesylamine: An inhibitor of famesylation and growth ofras-transformed cells. Lipids, 1993, 28, 969-973.	0.7	29
147	In Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast Cancer. Translational Oncology, 2012, 5, 217-225.	1.7	29
148	Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL-60 cells. , 1998, 175, 229-237.		28
149	Mapping of the functional microcirculation in vital organs using contrast-enhanced in vivo video microscopy. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H185-H193.	1.5	28
150	Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns. Laboratory Investigation, 2010, 90, 1247-1258.	1.7	28
151	TBX3 promotes progression of preâ€invasive breast cancer cells by inducing EMT and directly upâ€regulating SLUG. Journal of Pathology, 2019, 248, 191-203.	2.1	28
152	Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU International, 2005, 96, 803-805.	1.3	27
153	The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clinical and Experimental Metastasis, 2011, 28, 309-317.	1.7	27
154	Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts their growth, survival and angiogenic potential. Nitric Oxide - Biology and Chemistry, 2015, 49, 26-39.	1.2	27
155	Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Research, 2003, 63, 4763-5.	0.4	27
156	Use of NeoR B16F1 murine melanoma cells to assess clonality of experimental metastases in the immune-deficient chick embryo. Clinical and Experimental Metastasis, 1988, 6, 171-182.	1.7	26
157	Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications. Journal of Molecular Medicine, 2014, 92, 5-12.	1.7	26
158	Co-Expression of Î±9Î²1 Integrin and VEGF-D Confers Lymphatic Metastatic Ability to a Human Breast Cancer Cell Line MDA-MB-468LN. PLoS ONE, 2012, 7, e35094.	1.1	26
159	Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer and Metastasis Reviews, 1998, 17, 263-269.	2.7	25
160	Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. International Journal of Oncology, 2009, 35, 297-308.	1.4	25
161	Therapeutic targets for antimetastatic therapy. Expert Opinion on Therapeutic Targets, 2004, 8, 527-536.	1.5	24
162	Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncology, 2006, 2, 627-641.	1.1	23

#	Article	IF	Citations
163	In vivo single scan detection of both ironâ€labeled cells and breast cancer metastases in the mouse brain using balanced steadyâ€state free precession imaging at 1.5 T. Journal of Magnetic Resonance Imaging, 2011, 34, 231-238.	1.9	23
164	Cyclin A2, a novel regulator of EMT. Cellular and Molecular Life Sciences, 2014, 71, 4881-4894.	2.4	23
165	The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. BMC Cancer, 2016, 16, 671.	1.1	23
166	Absence of hereditary mutations in exons 5 through 9 of the p53 gene and exon 24 of the neurofibromin gene in families with glioma. Annals of Neurology, 1994, 35, 120-122.	2.8	22
167	In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis, 2004, 7, 157-164.	3.7	22
168	Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biology and Therapy, 2005, 4, 1336-1341.	1.5	22
169	The Role of Osteopontin in the Development of Granulomatous Lesions in Lung. Microbiology and Immunology, 2000, 44, 319-332.	0.7	21
170	Role of plasma osteopontin as a biomarker in locally advanced breast cancer. American Journal of Translational Research (discontinued), 2015, 7, 723-32.	0.0	21
171	Tumor Metastasis to the Liver, and the Roles of Proteinases and Adhesion Molecules: New Concepts from In Vivo Videomicroscopy. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 733-743.	1.8	19
172	Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment. Translational Oncology, 2016, 9, 219-227.	1.7	19
173	Someras-transformed cells have increased radiosensitivity and decreased repair of sublethal radiation damage. Somatic Cell and Molecular Genetics, 1990, 16, 39-48.	0.7	18
174	O6-Methylguanine-DNA Methyltransferase in Tumors and Cells of the Oligodendrocyte Lineage. Canadian Journal of Neurological Sciences, 1995, 22, 111-115.	0.3	18
175	Experimental Metastasis Assays in the Chick Embryo. Current Protocols in Cell Biology, 2003, 21, Unit 19.6.	2.3	18
176	Tumor-Î±9Î²1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts. Journal of Molecular Medicine, 2014, 92, 1271-1281.	1.7	18
177	ras Transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells. Clinical and Experimental Metastasis, 1990, 8, 417-431.	1.7	17
178	Expression of Antisense Osteopontin RNA in Metastatic Mouse Fibroblasts Is Associated with Reduced Malignancy. Annals of the New York Academy of Sciences, 1995, 760, 299-301.	1.8	17
179	Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. , 2000, 76, 71-83.		17
180	Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin. , 2000, 78, 8-23.		17

#	Article	IF	Citations
181	Contrast-Enhanced Microcomputed Tomography Using Intraperitoneal Contrast Injection for the Assessment of Tumor-Burden in Liver Metastasis Models. Investigative Radiology, 2008, 43, 488-495.	3.5	17
182	MRI surveillance of cancer cell fate in a brain metastasis model after early radiotherapy. Magnetic Resonance in Medicine, 2017, 78, 1506-1512.	1.9	17
183	Ex-vivo cellular MRI with b-SSFP: quantitative benefits of 3ÂT over 1.5ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 251-259.	1.1	16
184	Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. International Journal of Oncology, 2009, , .	1.4	15
185	Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 887-888.	3.3	15
186	Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 727-734.	1.5	15
187	Detection of Various Epitopes of Murine Osteopontin by Monoclonal Antibodies. Biochemical and Biophysical Research Communications, 1999, 257, 6-11.	1.0	14
188	Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin Î±vÎ²3 in mucoepidermoid carcinoma and acinic cell adenocarcinoma of salivary gland origin. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, 320-329.	0.2	14
189	Effects of long-chain fatty amines on the growth of ras-transformed NIH 3T3 cells. Biochemical Pharmacology, 1994, 47, 1909-1916.	2.0	13
190	Osteopontin expression in salivary gland tumours. Oral Oncology, 2006, 42, 363-369.	0.8	13
191	Radiation-induced lung injury after concurrent neoadjuvant chemoradiotherapy for locally advanced breast cancer. Acta OncolÃ³gica, 2014, 53, 697-701.	0.8	13
192	Technical Note: Immunohistochemical evaluation of mouse brain irradiation targeting accuracy with 3Dâ€printed immobilization device. Medical Physics, 2015, 42, 6507-6513.	1.6	13
193	O 6 -Methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. Carcinogenesis, 1999, 20, 2361-2365.	1.3	12
194	Breast cancer metastasis progression as revealed by intravital videomicroscopy. Expert Review of Anticancer Therapy, 2006, 6, 1271-1279.	1.1	12
195	Imaging the Impact of Chemically Inducible Proteins on Cellular Dynamics In Vivo. PLoS ONE, 2012, 7, e30177.	1.1	12
196	Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin Î±vÎ²3 in pleomorphic adenoma, polymorphous low-grade adenocarcinoma, and adenoid cystic carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 116, 743-751.	0.2	12
197	Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	11
198	Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis. Laboratory Investigation, 2020, 100, 400-413.	1.7	11

#	Article	IF	Citations
199	Angiogenesis as a target for breast cancer therapy. Journal of Mammary Gland Biology and Neoplasia, 1999, 4, 415-423.	1.0	10
200	Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis. Cancer Genetics and Cytogenetics, 2008, 181, 1-7.	1.0	10
201	Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Research, 2008, 10, 114.	2.2	9
202	Chapter 9 Intravital Videomicroscopy in Angiogenesis Research. Methods in Enzymology, 2008, 444, 201-230.	0.4	9
203	Mechanisms of oncogene-mediated alterations in metastatic ability. Biochemistry and Cell Biology, 1992, 70, 817-821.	0.9	8
204	Regulation and Function of Osteopontin in Ras-Transformed Cells. Annals of the New York Academy of Sciences, 1995, 760, 101-108.	1.8	8
205	Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models. Cancer Biology and Therapy, 2011, 12, 680-690.	1.5	8
206	Primary melanoma tumor inhibits metastasis through alterations in systemic hemostasis. Journal of Molecular Medicine, 2016, 94, 899-910.	1.7	8
207	Cancer dissemination from a physical sciences perspective. Convergent Science Physical Oncology, 2016, 2, 023001.	2.6	8
208	Rates of generation of methotrexate-resistant variants in cells temperature-sensitive for malignant transformation. Somatic Cell and Molecular Genetics, 1988, 14, 253-259.	0.7	6
209	Modulation of clonal progression in B16F1 melanoma cells. Clinical and Experimental Metastasis, 1991, 9, 151-162.	1.7	6
210	Compound speckle model detects antiâ€angiogenic tumor response in preclinical nonlinear contrastâ€enhanced ultrasonography. Medical Physics, 2017, 44, 99-111.	1.6	6
211	Evaluating the role of serine protease inhibition in the management of tumor micrometastases. Oncology, 2003, 17, 9-30; quiz 31-2.	0.4	6
212	Gene expression and metastasis of somatic cell hybrids between murine fibroblast cell lines of different malignant potential. Somatic Cell and Molecular Genetics, 1991, 17, 377-389.	0.7	5
213	Half brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response. Radiation Oncology, 2018, 13, 104.	1.2	5
214	Anticarcinogenic Activities of Naturally Occurring Cysteine Proteinase Inhibitors. , 1993, , 199-216.		5
215	A Monoclonal Antibody against Osteopontin Inhibits RGD-Mediated Cell Adhesion to Osteopontin. Annals of the New York Academy of Sciences, 1995, 760, 309-311.	1.8	4
216	Restriction Enzyme Analysis of DNA Methylation in â€œCondensedâ€•Chromatin of Ha-Ras-Transformed NIH 3T3 Cells. Analytical Cellular Pathology, 2000, 20, 163-171.	2.1	4

#	Article	IF	Citations
217	Malignant properties of P635 glioma are independent of glial fibrillary acidic protein expression. Journal of Neuro-Oncology, 1991, 11, 43-48.	1.4	3
218	Tumor Dormancy, Metastasis, and Cancer Stem Cells. , 2009, , 141-153.		3
219	Progression of Early Breast Cancer to an Invasive Phenotype. , 2013, , 143-159.		2
220	A Method to Validate Quantitative High-Frequency Power Doppler Ultrasound With Fluorescence inÂVivo Video Microscopy. Ultrasound in Medicine and Biology, 2014, 40, 1908-1917.	0.7	2
221	Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo. Journal of Visualized Experiments, 2015, , .	0.2	2
222	Prevention of Conversion of Tumor Dormancy into Proliferative Metastases. Current Cancer Research, 2016, , 121-137.	0.2	2
223	Tumor Dormancy in Liver Metastasis: Clinical and Experimental Evidence and Implications for Treatment. Cancer Metastasis - Biology and Treatment, 2011, , 213-232.	0.1	2
224	Re: Medroxyprogesterone Acetate and Metastases: Of Mice and (Wo)Men. Journal of the National Cancer Institute, 2005, 97, 1225-1225.	3.0	1
225	A compound speckle model for vascular complexity quantification in nonlinear contrast-enhanced ultrasonography. , 2014, , .		1
226	Improved Linear Contrast-Enhanced Ultrasound Imaging via Analysis of First-Order Speckle Statistics. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2016, 63, 1409-1421.	1.7	1
227	Image analysis of feulgen-stained -transformed NIH 3T3 cell clones. Cell Biology International Reports, 1990, 14, 174.	0.7	0
228	Title is missing!. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 373-374.	1.0	0
229	Distinct karyotypes in three breast cancer cell lines â€" 21PTCi, 21NTCi, and 21MT-1 â€" derived from the same patient and representing different stages of tumor progression. Cancer Genetics and Cytogenetics, 2008, 186, 33-40.	1.0	0
230	Metastasis: a current perspective. , 2008, , 1-10.		0
231	Introduction to special issue on â€˜epigenetic and physiological regulation of metastasisâ€™. Clinical and Experimental Metastasis, 2009, 26, 3-4.	1.7	0
232	Metastatic Inefficiency and Tumor Dormancy. , 0, , 148-154.		0
233	In vivo evaluation of an objective method to select power Doppler wall filter cut-off frequency for microvascular quantification. , 2014, , .		0
234	MP35-15 DEVELOPING A PATIENT-DERIVED XENOGRAFT MODEL USING CHICKEN EMBRYOS TO PREDICT TARGETED THERAPY TUMOR RESISTANCE IN RENAL CELL CARCINOMAS. Journal of Urology, 2014, 191, .	0.2	0

#	Article	IF	Citations
235	Tumor metastasis, physical sciences and the value of multidisciplinary collaborations. Convergent Science Physical Oncology, 2016, 2, 030501.	2.6	0
236	Circulating Tumor Cells and Tumor Dormancy. Current Cancer Research, 2016, , 101-120.	0.2	0
237	WE-D-I-609-07: Analysis of Growth Dynamics of Treated Murine Liver Metastases Using Volumetric Ultrasound Micro-Imaging. Medical Physics, 2005, 32, 2134-2134.	1.6	0
238	A New Breast Cancer Model for Lymphatic Metastasis. Cancer Treatment and Research, 2007, 135, 157-165.	0.2	0
239	Genes and metastasis: experimental advances and clinical implications. , 2008, , 33-58.		0
240	Preclinical Liver Metastases: Three-Dimensional High-Frequency Ultrasound Imaging. , 2009, , 369-386.		0
241	Liver Metastases. , 2013, , 141-161.		0
242	Dormancy and Metastasis of Melanoma Cells to Lymph Nodes, Lung and Liver. , 2013, , 63-78.		0
243	Interactions of Normal Tissues and Systems with Metastatic Cells: Impact on Location, Survival and Growth. , 2013, , 11-27.		0
244	Abstract 4716: Discovery of biomarkers from highly enriched prostate cancer microparticles for prognostication of prostate cancer. , 2014, , .		0
245	Abstract 3119: Predicting drug resistance in metastatic renal cell carcinoma: Personalized medicine by xenografting patient tumors into chicken embryos. , 2014, , .		0
246	Abstract 4055: The transcriptional regulator TBX3 promotes progression of cells representing early premalignant breast cancer. , 2014, , .		0
247	Abstract 3432: A genome-wide shRNA screen for suppressors of prostate cancer cell invasion. , 2014, , .		0